Electronic Drug Delivery Systems Market

The report "Electronic Drug Delivery Systems Market By Type (Electronic Wearable Infusion Pump, Autoinjectors, Injection Pens, Electronic Inhalers), Indication (Diabetes, Multiple Sclerosis, Cardiovascular Disease, Asthma & COPD) - Global Forecast to 2024" The electronic drug delivery systems market is projected to grow at a CAGR of 8.7% during the forecast period to reach USD 11.9 billion by 2024 from USD 7.8 billion in 2019. Factors such as the growing prevalence of target diseases, the favorable reimbursement scenario in major markets, and advancements in technologies & designs of electronic drug delivery systems are driving the growth of the electronic drug delivery systems market during the forecast period. However, emerging economies such as China, India, Russia, and Brazil offer significant growth opportunities for players in the electronic drug delivery market. This can primarily be attributed to the diversified healthcare markets in this region, growing incidence of chronic disorders, and increasing R&D initiatives to develop innovative medical technologies.

Browse 86 market data Tables and 32 Figures spread through 125 Pages and in-depth TOC on "Electronic Drug Delivery Systems Market By Type (Electronic Wearable Infusion Pump, Autoinjectors, Injection Pens, Electronic Inhalers), Indication (Diabetes, Multiple Sclerosis, Cardiovascular Disease, Asthma & COPD) - Global Forecast to 2024"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/electronic-drug-delivery-system-market-165758442.html

Electronic Wearable Infusion Pumps are expected to be the most widely used type of system in the Electronic Drug Delivery Systems market

The electronic wearable infusion pumps segment accounted for the largest share of the electronic drug delivery systems market in 2018. This is primarily due to the rising prevalence of diabetes and the increasing availability of commercial infusion pumps for diabetes treatment. However, the high cost of electronic drug delivery devices, high acceptance of conventional devices, and lack of reimbursement for electronic drug delivery devices in developing countries could restrain the growth of this segment.

Diabetes segment is expected to account for the largest share of the electronic drug delivery system market by indication

The diabetes segment accounted for the largest share in 2018. This is primarily due to the high prevalence of diabetes across the globe and the greater availability of electronic drug delivery devices, such as insulin pumps and injection pens, for diabetes in comparison to other therapeutic areas. For instance, according to the International Diabetes Federation, in 2017, almost 425 million people were suffering from diabetes worldwide; this is expected to increase to 629 million by 2045.

North America to dominate the electronic drug delivery systems market during the forecast period

In 2018, North America dominated the electronic drug delivery systems market, followed by Europe. High burden of target diseases, favorable reimbursement scenario, and the presence of major market players in this region are the factors propelling the growth of the market. For instance, in April 2018, AstraZeneca (UK) received OTC clearance for its SmartTouch for Symbicort (an electronic inhaler) and launched this product in the US market. Similarly, in December 2017, Companion Medical (US), launched InPen (an electronic injection pen) in the US.

The prominent players in the electronic drug delivery systems market are Insulet Corporation (US), Bayer AG (Germany), Medtronic (Ireland), Novo Nordisk A/S (Denmark), Companion Medical (US), F.Hoffmann-La Roche Ltd (Switzerland), United Therapeutics Corporation (US), AstraZeneca (UK), Tandem Diabetes Care (US), Merck Group (Germany), and Amgen (US).

Don’t miss out on business opportunities in Electronic Drug Delivery Systems Market. Speak to our analyst and gain crucial industry insights that will help your business grow.

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]